The study enrolled 1,174 patients who were randomized 2 vs.1 to receive either: KEYTRUDA (every three weeks) plus paclitaxel (weekly) and carboplatin (weekly or every three weeks) for four cycles, followed by KEYTRUDA plus cyclophosphamide and either doxorubicin or epirubicin
(every three weeks) for four cycles as neoadjuvant therapy prior to surgery, followed by nine cycles of KEYTRUDA (every three weeks) as adjuvant therapy post-surgery or; placebo (every three weeks) plus paclitaxel (weekly) and carboplatin (weekly or every three weeks) for four cycles, followed by placebo plus cyclophosphamide and either doxorubicin or epirubicin
(every three weeks) for four cycles, followed by nine cycles of placebo (every three weeks) as adjuvant therapy post-surgery.
Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer Patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin
, and fluorouracil: Danish Breast Cancer Cooperative Group.
The superiority of any of the IVCT agents (mitomycin C, epirubicin
, pirarubicin, and thiotepa) to one another has yet to be demonstrated (29).
Similarly microorganisms have a potential to produce unique substances that prompted the revelation of antibacterial agents like cephalosporin's, antidiabetic agent such as acarbose and anticancer drug lead such as epirubicin
(Murugesan et al., 2013).
Common chemotherapeutic drugs used in this study were: cetuximab, gefitinib, imatinib, sorafenib, paclitaxel, vincristine, vinblastine, 6-mercaptopurine, 5-fluorouracil, cytarabine, capecitabine, gemcitabine, cisplatin, carboplatin, oxaliplatin, etoposide, cyclophosphamide, doxorubicin, daunorubicin, epirubicin
, hydroxyurea, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimens.
Patients received either four cycles of DTX (75 mg/[m.sup.2] on day 1; group A) (Taxotere[R]: Sanofi K.K.) every 3 weeks, or four cycles of nab-PTX (100 mg/[m.sup.2] on days 1, 8, and 15; group B) (Abraxane[R]: TAIHO Pharmaceutical Co., Ltd) every 4 weeks, followed by four cycles of FE100C (5-fluorouracil 500 mg/[m.sup.2], epirubicin
100 mg/[m.sup.2], cyclophosphamide 500 mg/[m.sup.2] every 3 weeks) (Fluorouracil[R]:Kyowa Hakko Kirin Co.
The patient was treated with rituximab, cyclophosphamide, epirubicin
, vindesine, and prednisone for 6 courses and remained in partial remission till now.
This cancer was considered a new primary, and the patient received neoadjuvant FEC (fluorouracil, epirubicin
, cyclophosphamide) and docetaxel.
Sensitivity was high for the chemotherapy protocol Fluorouracil, Epirubicin
, Cyclophosphamide, Docetaxel (FEC-D; 71.9%) but lower for all others (65.3% for Adriamycin, Cyclophosphamide, Paclitaxel [ACP]/Adriamycin, Cyclophosphamide, Taxol [ACT], 62.5% for Fluorouracil, Epirubicin
, Cyclophosphamide [FEC], 60.6% for Adriamycin, Cyclophosphamide [AC], and 50.7% for Taxotere, Cyclophosphamide or Carboplatin [TC]), while specificity was greater than 94% for all chemotherapy protocols.
The patient required 8 courses of immunochemotherapy (rituximab-cyclophosphamide, epirubicin
, vincristine, and prednisone) and achieved complete remission  (see Table 1).
38 patients had received 90 mg/[m.sup.2] epirubicin
for 4 cycles, 5 patients had received epirubicin
100 mg/[m.sup.2] for 6 cycles, and 2 patients had received doxorubicin 50 mg/[m.sup.2] for 6 cycles.
Chemotherapy regimen Patients (number) ECF (epirubicin
, cisplatin, and 16 5-fluorouracil) DOX (docetaxel, oxaliplatin, and 46 capecitabine) EOX (capecitabine, oxaliplatin, and 7 ED epirubicin
) DCF (docetaxel, cisplatin, and 2 5-fluorouracil) 2ECF + 4DCF 1 CDDP(cisplatin) + capecitabine 1 FOLFOX (folic acid, fluorouracil, 9 and oxaliplatin) 1 DOX + 3 DOF (docetaxel, oxaliplatin, 1 and fluorouracil) EOF (epirubicin
, oxaliplatin, and 3 5-fluorouracil) Table 2: List of tomographs adopted in the study.